| Login | Create Account | Leaders | Stock Exchange | News | How to Play |
| Oztec | Bonno Hinchclif, CEO | |||
|
Development of a bionic heart with ambitions to take technology to worldwide medical market |
||||
| Quote: | Analyst Ratings: | |||
|---|---|---|---|---|
|
Intraday Price: Last Close: Symbol: Sector: Dividend Yield: Market Cap: Shares Float: Total Assets: Annual Earnings: Price/Earnings: Cash: |
$27.98 (+0.00%) $27.98 (+4.13%) OZ Biotechnology 2.0% $2.10 billion 75.00 million $1.13 billion -$111.18 billion -0.01 -$76.34 million |
Goldsmith Maxx focuses on company cash, debt, dividend, liabilities, and legal proceedings. Goldsmith Maxx: Satisfactory KT Sorenson emphasizes revenue, profit, income, and cash flow. KT Sorenson: Excellent Jordin Gann observes company officers, management, operational efficiency, and direction. Jordin Gann: Excellent Walter Lane Financial projects future earnings based upon news and events. Walter Lane Financial: Good Harlin-Hall Group analyzes operating and profit margins and potential returns on equity and assets. Harlin-Hall Group: Poor Solomon Stoan tracks business growth and expansion. Solomon Stoan: Good |
||
|
View Top Competitors |
||||